Australian Pharma Industry “Astonished” By Call To Cut Patent-Term Extensions
This article was originally published in PharmAsia News
A government draft report stuns the industry by calling for restrictions on patent-term extensions as a battle heats up on how to control costs under Australia’s Pharmaceutical Benefits Scheme.
You may also be interested in...
A storm is brewing in the lead up to Australia's May 10 federal budget over the nation's Pharmaceutical Benefits Scheme, which acts as a single payer to subsidize drug prices and is administered by the government
Cynata has inched closer to a major global partnership after signing a term sheet with Fujifilm for cell therapy technologies that has been described by analysts as a potentially transformative deal.
As a former war correspondent on the battlefields of the Balkans, Afghanistan and Iraq, new Avita Medical chief executive Adam Kelliher can claim to have an up-close understanding of the types of injuries that his regenerative medicine company’s lead product is designed to heal.